GlassScriptPhysician profile
Gary S Inamine
NPI 1013060698
$18,557.98
in general payments reported to CMS, 2019-2025
30 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,292 · 2020: $3,616 · 2021: $3,602 · 2022: $2,640 · 2023: $2,194 · 2024: $1,763 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,406.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $2,966.68 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $2,656.70 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,997.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,492.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,488.61 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $1,451.87 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $1,387.39 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Lilly USA, LLC | $874.23 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $516.93 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $498.54 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $482.35 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $404.80 | 2023-2025 | |
| Esperion Therapeutics, INC. | $391.56 | 2020-2024 | Nexletol |
| Allergan, INC. | $257.84 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $256.46 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $219.68 | 2022 | |
| Novartis Pharmaceuticals Corporation | $203.69 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $188.03 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $157.10 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $144.32 | 2019-2025 | Dupixent |
| Arbor Pharmaceuticals, INC. | $143.05 | 2019-2021 | |
| Medicure Pharma INC. | $94.55 | 2020-2021 | |
| Radius Health, INC. | $63.77 | 2019-2020 | |
| Genentech USA, INC. | $43.20 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $42.72 | 2020 | |
| Exact Sciences Corporation | $36.94 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $32.15 | 2019 | |
| Boston Scientific Corporation | $27.14 | 2025 | Watchman Access System |
| Eisai INC. | $24.85 | 2021 | |
| Horizon Therapeutics Plc | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Inamine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.